AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
paper
Cited
Public
Unavailable
- Authors
- Ljung, Bengt; Bamberg, Krister; DahllΓΆf, BjΓΆrn; Kjellstedt, Ann; Oakes, Nicholas D; Ostling, JΓΆrgen; Svensson, Lennart; Camejo, GermΓ‘n
- Year
- 2002
- Journal
- Journal of lipid research
- PMID
- 12401884
- DOI
- 10.1194/jlr.m200127-jlr200
Abnormalities in fatty acid (FA) metabolism underlie the development of insulin resistance and alterations in glucose metabolism, features characteristic of the metabolic syndrome and type 2 diabetes that can result in an increased risk of cardiovascular disease. We present pharmacodynamic effects of AZ 242, a novel peroxisome proliferator activated receptor (PPAR)alpha/gamma agonist. AZ 242 dose-dependently reduced the hypertriglyceridemia, hyperinsulinemia, and hyperglycemia of ob/ob diabetic mice. Euglycemic hyperinsulinemic clamp studies showed that treatment with AZ 242 (1 micromol/kg/d) restored insulin sensitivity of obese Zucker rats and decreased insulin secretion. In vitro, in reporter gene assays, AZ 242 activated human PPARalpha and PPARgamma with EC(50) in the micro molar range. It also induced differentiation in 3T3-L1 cells, an established PPARgamma effect, and caused up-regulation of liver fatty acid binding protein in HepG-2 cells, a PPARalpha-mediated effect. PPARalpha-mediated effects of AZ 242 in vivo were documented by induction of hepatic cytochrome P 450-4A in mice. The results indicate that the dual PPARalpha/gamma agonism of AZ 242 reduces insulin resistance and has beneficial effects on FA and glucose metabolism. This effect profile could provide a suitable therapeutic approach to the treatment of type 2 diabetes, metabolic syndrome, and associated vascular risk factors.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Understanding PPARΞ³ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia. | Qin Y et al. | β | 2023 | β |
| Advantages and drawbacks of dexamethasone in glioblastoma multiforme. | Afshari AR et al. | β | 2022 | β |
| Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances Ξ²-amyloid phagocytosis. | DeRidder L et al. | β | 2021 | β |
| <i>In vivo</i> liposomal delivery of PPARΞ±/Ξ³ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects. | Osinski V et al. | β | 2020 | β |
| NPY<sub>1</sub>R-targeted peptide-mediated delivery of a dual PPARΞ±/Ξ³ agonist to adipocytes enhances adipogenesis and prevents diabetes progression. | Wittrisch S et al. | β | 2020 | β |
| To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. | Sullivan HJ et al. | β | 2020 | β |
| Importance of thorough tissue and cellular level characterization of targeted drugs in the evaluation of pharmacodynamic effects. | Bauknight DK et al. | β | 2019 | β |
| Urate transporter inhibitor lesinurad is a selective peroxisome proliferator-activated receptor gamma modulator (sPPARΞ³M) in vitro. | Heitel P et al. | β | 2018 | β |
| Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor Ξ±/Ξ΄ (PPARΞ±/Ξ΄) dual agonists. | Shioi R et al. | β | 2017 | β |
| Development of an ELISA for High-Throughput Screening of Inhibitors of Cdk5-Mediated PPARΞ³ Phosphorylation. | Prokoph N et al. | β | 2016 | β |
| PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice. | Blednov YA et al. | β | 2016 | β |
| The peroxisome proliferator-activated receptorΒ Ξ± agonist, AZD4619, induces alanine aminotransferase-1 gene and protein expression in human, but not in rat hepatocytes: Correlation with serum ALT levels. | Thulin P et al. | β | 2016 | β |
| Transition-Metal-Catalyzed Asymmetric Hydrogenation and Transfer Hydrogenation: Sustainable Chemistry to Access Bioactive Molecules. | Ayad T et al. | β | 2016 | β |
| Efficient Synthesis of Differentiated syn-1,2-Diol Derivatives by Asymmetric Transfer Hydrogenation-Dynamic Kinetic Resolution of Ξ±-Alkoxy-Substituted Ξ²-Ketoesters. | Monnereau L et al. | β | 2015 | β |
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | β | 2015 | β |
| Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes. | Baker DJ et al. | β | 2014 | β |
| Inhibition of AMP deaminase activity does not improve glucose control in rodent models of insulin resistance or diabetes. | Admyre T et al. | β | 2014 | β |
| PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption. | Ferguson LB et al. | β | 2014 | β |
| Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs. | Velkov T | β | 2013 | β |
| Potent anti-diabetic effects of MHY908, a newly synthesized PPAR Ξ±/Ξ³ dual agonist in db/db mice. | Park MH et al. | β | 2013 | β |
| The g0/g1 switch gene 2 is an important regulator of hepatic triglyceride metabolism. | Wang Y et al. | β | 2013 | β |
| The PPAR Ξ± / Ξ³ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat. | Wallenius K et al. | β | 2013 | β |
| Comprehensive evidence-based assessment and prioritization of potential antidiabetic medicinal plants: a case study from canadian eastern james bay cree traditional medicine. | Haddad PS et al. | β | 2012 | β |
| Human target validation of phosphoinositide 3-kinase (PI3K)Ξ²: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3KΞ² inhibitor. | Nylander S et al. | β | 2012 | β |
| Tesaglitazar, a dual PPAR-Ξ±/Ξ³ agonist, hamster carcinogenicity, investigative animal and clinical studies. | Lindblom P et al. | β | 2012 | β |
| Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. | Chen H et al. | β | 2010 | β |
| The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. | Reddy KJ et al. | β | 2010 | β |
| New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. | Fracchiolla G et al. | β | 2009 | β |
| P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice. | Chen W et al. | β | 2009 | β |
| Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. | Casimiro-Garcia A et al. | β | 2009 | β |
| Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies. | Casimiro-Garcia A et al. | β | 2008 | β |
| PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. | Kim MK et al. | β | 2008 | β |
| Synthesis of polymeric thiazolidinedione and fibrate conjugates. | Kim Y et al. | β | 2008 | β |
| Thiazolidinediones: effects on insulin resistance and the cardiovascular system. | Quinn CE et al. | β | 2008 | β |
| Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake. | Hu X et al. | β | 2007 | β |
| Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. | Cha DR et al. | β | 2007 | β |
| Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. | Chira EC et al. | β | 2007 | β |
| Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. | Hellmold H et al. | β | 2007 | β |
| The importance of plasma protein binding in drug discovery. | Trainor GL | β | 2007 | β |
| A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. | Burgermeister E et al. | β | 2006 | β |
| Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. | Hu X et al. | β | 2006 | β |
| Anti-diabetic properties of the Canadian lowbush blueberry Vaccinium angustifolium Ait. | Martineau LC et al. | β | 2006 | β |
| Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar. | Sharma S et al. | β | 2006 | β |
| Cytochrome P450 and xenobiotic receptor humanized mice. | Gonzalez FJ et al. | β | 2006 | β |
| Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. | Zadelaar AS et al. | β | 2006 | β |
| Insulin resistance--a common link between type 2 diabetes and cardiovascular disease. | Lebovitz HE | β | 2006 | β |
| Insulin stimulates arterial neointima formation in normal rats after balloon injury. | Foster E et al. | β | 2006 | β |
| Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes. | Savkur RS et al. | β | 2006 | β |
| Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. | Harrity T et al. | β | 2006 | β |
| PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. | Edvardsson U et al. | β | 2006 | β |
| PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents. | Lanne B et al. | β | 2006 | β |
| PPARgamma as a new therapeutic target in inflammatory bowel diseases. | Dubuquoy L et al. | β | 2006 | β |
| Recent findings concerning thiazolidinediones in the treatment of diabetes. | Boden G et al. | β | 2006 | β |
| Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. | Pourcet B et al. | β | 2006 | β |
| Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid. | Cai ZF et al. | β | 2006 | β |
| The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. | Seber S et al. | β | 2006 | β |
| Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. | Chapman MJ | β | 2006 | β |
| 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. | MartΓn JA et al. | β | 2005 | β |
| Drugs on the horizon for diabesity. | Bailey CJ | β | 2005 | β |
| Fructose feeding increases insulin resistance but not blood pressure in Sprague-Dawley rats. | D'Angelo G et al. | β | 2005 | β |
| Novel pharmacologic agents for type 2 diabetes. | Uwaifo GI et al. | β | 2005 | β |
| Pathway proteomics: global and focused approaches. | Marko-Varga G | β | 2005 | β |
| Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. | Fenner MH et al. | β | 2005 | β |
| Rational drug design and PPAR agonists. | Perfetti R et al. | β | 2005 | β |
| Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. | Oakes ND et al. | β | 2005 | β |
| Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. | Fagerberg B et al. | β | 2005 | β |
| The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. | Pickavance LC et al. | β | 2005 | β |
| Therapeutic roles of peroxisome proliferator-activated receptor agonists. | Staels B et al. | β | 2005 | β |
| Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. | Carmena R | β | 2005 | β |
| 1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility. | Henke BR | β | 2004 | β |
| A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. | Sakamoto J et al. | β | 2004 | β |
| Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model. | Rybczynski PJ et al. | β | 2004 | β |
| Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. | Cheung C et al. | β | 2004 | β |
| [Future targets in the treatment of type 2 diabetes]. | Stingl H et al. | β | 2004 | β |
| Impact of age on cardiovascular risk: implications for cardiovascular disease management. | Tuomilehto J | β | 2004 | β |
| Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists. | Gervois P et al. | β | 2004 | β |
| Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. | Yajima H et al. | β | 2004 | β |
| Lipids and glucose in type 2 diabetes: what is the cause and effect? | Boden G et al. | β | 2004 | β |
| Novel strategies for the pharmacological management of type 2 diabetes. | Nourparvar A et al. | β | 2004 | β |
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. | Henke BR | β | 2004 | β |
| Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar. | Hegarty BD et al. | β | 2004 | β |
| Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. | Minoura H et al. | β | 2004 | β |
| Thiazolidinediones. | Yki-JΓ€rvinen H | β | 2004 | β |
| Genotype, obesity and cardiovascular disease--has technical and social advancement outstripped evolution? | Zimmet P et al. | β | 2003 | β |
| New lipid-modifying therapies. | Bruckert E | β | 2003 | β |
| Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. | Plutzky J | β | 2003 | β |
| Pharmacotherapy for dyslipidaemia--current therapies and future agents. | Bays H et al. | β | 2003 | β |